ALEC insider sale notice: 50,242 shares via Morgan Stanley
Rhea-AI Filing Summary
Alector, Inc. insider sale notice: The filing reports that 50,242 shares of Alector common stock will be offered for sale via Morgan Stanley Smith Barney, with an aggregate market value of $118,068.70 and an approximate sale date of 09/02/2025. The shares were acquired on 08/29/2025 upon vesting of restricted stock units totaling 98,939 shares; payment was recorded on the same date. The company has 101,212,329 shares outstanding, so the planned sale represents about 0.05% of outstanding shares. The filer also reported a prior sale on 06/02/2025 of 52,087 shares for $69,713.24. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
Positive
- Timely disclosure of proposed sale under Rule 144, including broker details and acquisition method
- Use of a registered broker (Morgan Stanley Smith Barney) for execution, indicating standard market procedure
Negative
- Insider selling activity with a recent prior sale (52,087 shares on 06/02/2025) which may warrant monitoring for trends
- Form does not state whether the sales are part of a 10b5-1 trading plan (no plan adoption date provided)
Insights
TL;DR: Routine post-vesting insider sale disclosed; small relative size and prior recent sale suggest limited market impact.
The filing documents a scheduled sale of 50,242 shares following vesting of 98,939 restricted stock units on 08/29/2025. At an aggregate value of $118,068.70 against 101.2 million shares outstanding, the transaction is immaterial to market capitalization. The use of a major broker for execution and formal Rule 144 notice indicate compliance with resale requirements. Recent disposition of 52,087 shares on 06/02/2025 is disclosed, which is relevant for monitoring insider selling patterns but does not by itself indicate material corporate change.
TL;DR: Proper procedural disclosure under Rule 144; governance implication is routine but should be tracked for insider activity trends.
The signer attests no undisclosed material adverse information is known and the form lists broker execution details and acquisition method (RSU vesting). This is consistent with compliant insider reporting. While multiple recent sales are disclosed, each transaction is small relative to total shares outstanding. Governance focus should be on whether these sales follow a documented trading plan, though the form does not indicate a 10b5-1 plan adoption date.